Skip to main content
Premium Trial:

Request an Annual Quote

Higher, But Cautious

Biotech stocks are climbing high, but Reuters' Deena Beasley writes that a nearly 50 percent increase in the last year has stoked worries about a bubble. She notes that the Nasdaq Biotech Index is up 45 percent as compared to last year and the Pharmaceutical Index is similarly up 32 percent, while during the same timeframe, the S&P 500 Index gained 25 percent.

"Genetic information is providing a big opportunity for new drug development," Rajiv Kaul, portfolio manager of Fidelity Investments Select Biotechnology Portfolio, tells her. "There are exciting new opportunities, but you also need to be careful because most drugs fail."

David Heupel from Thrivent Investment Management adds that the space "has some room to grow, but it is not going to be as easy as it has been."

Consensus estimates, though, say that the annual average combined earnings growth for biotechs for the next three years will be 21 percent, as compared to 9 percent for S&P 500 companies, Beasley writes.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.